Evidence map›Paper›PMID 40106068›Full record

ArticleClinical and experimental medicine2025

MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial-mesenchymal transition in hepatocellular carcinoma.

Wenyuan Zhu, Qingqiang Ni, Zhengjian Wang, Ruxuan Zhang, Fangfeng Liu, Hong Chang

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenyuan ZhuDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China.
Qingqiang NiDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China.
Zhengjian WangDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China.
Ruxuan ZhangDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China.
Fangfeng LiuDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China. liufangfeng@sdfmu.edu.cn.
Hong ChangDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China. changhong@sdfmu.edu.cn.

Funding

Ethics Committee of Shandong Provincial Hospital SWYX:NO.2022-477
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate numerous genes in cells. Abnormal expression of miRNAs can lead to cancer. However, the roles and underlying mechanisms of miRNAs in hepatocellular carcinoma (HCC) are not fully understood. Using molecular biology techniques, we designed eukaryotic expression vectors with enhanced expression of miR-101-3p to transfect human hepatocellular carcinoma cell lines. Subsequent to this, cell cloning experiments, CCK8 assays, and Transwell migration experiments were executed to assess their impact on liver cancer cell proliferation and invasion. Dual-luciferase assays were employed to validate the molecular interaction between miR-101-3p and Birc5. Through rescue experiments aimed at manipulating the expression levels of Birc5, we scrutinized the influence of miR-101-3p on liver cancer cell proliferation and invasion. Furthermore, Western blot analysis was utilized to monitor alterations in the expression levels of E-cadherin, N-cadherin, and vimentin proteins within each cell group. In vivo investigations were conducted using nude mice implanted with hepatocellular carcinoma cells transfected with Birc5. Additionally, further exploration was carried out by combining this model with the PI3K/AKT pathway inhibitor miltefosine to elucidate its effects on tumor proliferation. In vitro functional analysis of miR-101-3p revealed that treatment of HCC cells with its corresponding mimic significantly inhibited cell proliferation, colony formation, invasion, and epithelial-mesenchymal transition. Additionally, miR-101-3p exerts its anti-tumor effects by targeting the shared gene Birc5. Experiments using nude mouse models demonstrate that Birc5 promotes tumor proliferation by phosphorylating the PI3K/AKT signaling pathway. Inhibiting the PI3K/AKT signaling pathway shows suppressive effects on liver cancer proliferation. MiR-101-3p plays crucial roles in inhibiting the proliferation, invasion and epithelial-mesenchymal transition of HCC cells by targeting Birc5 and downregulating the PI3K-AKT signaling pathway. These findings provide new insights for the molecular treatment of HCC.

Indexed as

Carcinoma, HepatocellularEpithelial-Mesenchymal TransitionLiver NeoplasmsMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSurvivinAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMice, NudeBIRC5 protein, humanMicroRNAsMIRN101 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSurvivinBirc5Epithelial–mesenchymal transitionInvasionMetastasisMiR-101-3p

Identifiers

PMID40106068
PMCPMC11923034

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.